Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases.
Part of paid clinical trials in Palo Alto, California.
- Sponsor
- Stanford University
- Study ID
- NCT07594431
- Phase
- PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Metastases
- Metastatic Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 12 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- LATTICE Radiotherapy — RADIATION5-fraction LATTICE radiotherapy delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.
- Standard radiotherapy — RADIATIONStandard radiotherapy delivered to 25 Gy in 5 fractions.
Study Details
Unblinded, randomized study of 5-fraction LATTICE radiotherapy (20 Gy with an SIB to 66.7 Gy in 5 fractions) versus moderately dose-escalated palliative radiation (25 Gy in 5 fractions)
Key Dates
- Start date
- Aug 31, 2026
- Status verified
- May 2026
- Primary completion
- Aug 31, 2028
- Completion
- Aug 31, 2028
Study Design
- Enrollment
- 80 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: LATTICE RadiotherapyParticipants receive 5-fraction LATTICE radiotherapy delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.
- Active Comparator: Standard RadiotherapyParticipants receive standard radiotherapy (25 Gy in 5 fractions)
Primary Outcome Measure
Percent Tumor Volume Reduction Following Radiotherapy [ Time Frame: 90 +/- 20 days following radiotherapy ]
Central Contacts
- Jamie Wang650-497-4354
- Camellia Djebroun650-736-5564
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Stanford University | Palo Alto | California | 94304 | Michael Gensheimer, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Palo Alto, CA
By research site
Related Studies
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PHASE1/PHASE2 · Recruiting · PMV Pharmaceuticals, Inc · Irvine, California
- Imaging of Solid Tumors Using FAP-2286PHASE1 · Recruiting · Thomas Hope · San Francisco, California
- A Study of ART0380 for the Treatment of Advanced or Metastatic Solid TumorsPHASE1/PHASE2 · Recruiting · Artios Pharma Ltd · Birmingham, Alabama
- Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid TumorsPHASE1 · Recruiting · I-Mab Biopharma US Limited · Orange, California